BeiGene | Safety, Pharmacokinetics, and Antitumor Activity of BGB-B167 Alone and in Combination With Tislelizumab (BGB-A317) in Participants With Advanced Solid Tumors

Safety, Pharmacokinetics, and Antitumor Activity of BGB-B167 Alone and in Combination With Tislelizumab (BGB-A317) in Participants With Advanced Solid Tumors

Beigene Study ID

BGB-A317-B167-101

ClinicalTrials.gov ID

NCT05494762

Study Overview

Sex: All

Age: 18 Years / N/A

No Study Documents

Study Overview

Sex: All

Age: 18 Years / N/A

No Study Documents